First human study with vasopharm's trauma compound VAS203
11-Jan-2007
The goal of the upcoming phase I study which will start in January 2007 is to demonstrate safety, tolerability and pharmacokinetics of ascending single intravenous administrations of VAS203 in healthy volunteers. Provided that the enrolment of the volunteers proceeds as intended the results of the study are expected in June 2007. The single dose administration study will then be followed by a multiple dose study which is currently planned for July 2007.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
List_of_arctiid_genera:_P
Go to page
List_of_hesperiid_genera:M
Go to page
GENE-TRAK Listeria Microwell Test Receives AOAC Validation
Go to page
Neurochem announces departure of two members of management team
Go to page
List_of_prehistoric_cartilaginous_fish
Go to page
List_of_gelechiid_genera:_B
Go to page
American Chemical Society launches Prized Science video series
Go to page
List_of_chloropid_genera
Go to page
Biotime moves to new headquarters
Go to page
List_of_geometrid_genera
Go to page
List_of_geometrid_genera:_R
Go to page
Benzyl_benzoate
Go to page